Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Clinical evidence

OPERA-01

43 evidence topics · 11 sources

Objective
Location and study date
Registry dates
MilestoneRegistry record
Study start (actual)“2023-11-16”
Primary completion (estimated)“2026-10-31”
Study completion (estimated)“2028-02-29”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: registry record
Enrollment typeParticipants
Estimated“510”
Planned participants per arm
Part and armPlanned participants
Total“n = 510”
Part 1, each arm (palazestrant 90 mg, palazestrant 120 mg, standard-of-care endocrine therapy)“n = 40”
Part 2, each arm (palazestrant 90 mg, standard-of-care endocrine therapy)“n = 195 (total 235)”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No efficacy or safety results from OPERA-01 have been reported; enrollment is complete, and top-line results are anticipated in the first quarter of 2027. The trial is open label, with PFS assessed by blinded independent central review as the dual primary endpoint. The 90 mg Part 2 dose was chosen from Part 1 data with no formal statistical comparison. The control arm is endocrine monotherapy (fulvestrant or an aromatase inhibitor), and fulvestrant was recommended to participants who had not previously received it. Eligibility excludes participants with prior chemotherapy in the advanced or metastatic setting, prior elacestrant, or symptomatic visceral disease, permits at most one additional line of endocrine therapy after the endocrine therapy and CDK4/6 inhibitor combination, and requires the most recent endocrine therapy to have lasted at least 6 months. Participants receive a tablet formulation, whereas the earlier monotherapy data were obtained with capsules. The trial design publication was funded by Olema Oncology, which was involved in the study design.